Similar meta-analysis of the efficacy of CP therapy on different types of infectious disease found a 44% reduction in the mortality of patients with COVID-19 [208]; a 25% reduction in other severe acute respiratory infections [33]; and a 32% reduction in SARS-CoV infection, severe influenza, and Ebola infection [209]. The gene discussed is CP; the disease is influenza.